Tag Archives: Amgen

Biomedical Innovation in Trouble

The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH). This bleak picture of the “state of biomedical innovation” was painted by [...]
Posted in Biotech, FDA, R&D, Technology, healthcare, leadership | Also tagged , , , , | 3 Comments

Prolia: Runner Up in Pharm Exec Brand of the Year

This month, Pharm Exec magazine presents its Brand of the Year. Here, Brittany Agro profiles one of the runners-up, Amgen’s osteoporosis treatment, Prolia. A joint meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, held June 2005 in Geneva, Switzerland, revealed promising developments for more effective treatments in bone heath—specifically geared [...]
Posted in healthcare | Also tagged , , | 2 Comments

Saving Haiti: One Donation at a Time (UPDATED 1/21)

Image by American Red Cross via Flickr It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
Posted in News | Also tagged , , , , , , , | 2 Comments

GSK Signs $120M Deal to Market DMab Overseas

Image via Wikipedia In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval. GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]
Posted in Deals, News, Technology | Also tagged , , , , , , , , , , | 1 Comment